Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01935336
Recruitment Status : Unknown
Verified November 2019 by University of Colorado, Denver.
Recruitment status was:  Active, not recruiting
First Posted : September 5, 2013
Last Update Posted : November 20, 2019
Ariad Pharmaceuticals
Information provided by (Responsible Party):
University of Colorado, Denver

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Unknown
Actual Primary Completion Date : January 2017
Estimated Study Completion Date : December 2020
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 April 5, 2021
April 30, 2021
2 June 30, 2021
July 21, 2021
3 September 7, 2021
October 6, 2021
4 October 18, 2021
November 16, 2021
5 December 9, 2021
January 6, 2022
6 January 19, 2022